Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.

H. A. Burris, A.R. Abdul Razak, Maja J. De Jonge, F. Eskens, Lillian L. Siu, Qinhua Ru, Natasha F Homji, David Demanse, Emmanuelle di Tomaso, Jan Cosaert,

Journal of Clinical Oncology · 2011 · 20 citations · 0 references

Concepts

Abstract

3043 Background: PI3K pathway is frequently altered in cancer and can have an impact on tumor survival and proliferation. BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor without mTOR and Vps34 activity. Methods: Phase I dose-escalation (DE) study followed by an expansion cohort of daily BKM120 in pts with advanced solid tumors. Bayesian logistic regression model with overdose control guided the DE. Pts in the MTD expansion arm were pre-selected for molecular alterations of PI3K and/or PTEN. Results: 77 pts received oral BKM120 once daily thus far; data on 66 pts, median age 55 y (30-77), are reported here. 6 dose levels were explored: 12.5 mg (1 pt); 25 mg (2 pts), 50 mg (5 pts), 80 mg (11 pts), 100 mg (43 pts), 150 mg (4 pts). Most common tumor types: CRC (24 pts), breast cancer (BC) (18 pts), lung (3 pts) and endometrial (3 pts) cancer. Median duration of treatment was 7.5 wks (0.1-69+) with 18 pts treated for >16 wks. Seven dose-limiting toxicities (DLTs) were observed: 2x G4 hyperglycemia (150mg/d), 1x G3 upper abdominal pain, 1x G3 skin rash, 2x G2 and 1x G3 mood alteration. MTD was 100 mg/d. Most frequent AEs of all grades and suspected to be drug-related were decreased appetite (33%), rash, diarrhea, nausea (each 27%), fatigue, hyperglycemia (each 24%), anxiety (20%), depression (18%), and mucositis (17%). Mood alterations were successfully managed using self-rating questionnaires. pS6 suppression was found in skin in 100 and 150 mg cohorts (30 to 80% decreases from baseline). Increase of C-peptide was observed at all doses suggesting potential impairment of glucose transport by BKM120. Partial tumor responses were observed in 2 pts: one TN-BC with KRAS and p53 mutation, and one ER+/HER2 neg mBC harboring PIK3CA mutation. 58% pts (26 of 45 evaluable) had SD as best response. Eighteen pts had SD > 16 wks, including 8 pts who had tumors with an activated PI3K pathway. A trend towards better activity was observed at the higher dose cohorts, also expressed as metabolic FDG-PET response. Conclusions: BKM120 monotherapy was well tolerated and showed biological and antitumor activity. Further exploration of BKM120 in patients with PI3K pathway alteration is ongoing in endometrial and lung cancer pts.